Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Axsome Therapeutics, Inc. AXSM

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$638.5M
▲ 65.5% YoY
$-183.2M
$-93.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

It markets three FDA-approved commercial products for central nervous system conditions: AUVELITY, for major depressive disorder; SUNOSI, for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy; and SYMBRAVO, for the acute treatment of migraine with or without aura in adults. Total revenues from its three commercial products totaled $638.5 million for 2025. As of February 16, 2026, it had 925 full-time employees. Its lead product candidate, AXS-05, a combination of dextromethorphan and bupropion, is currently being developed for the treatment of Alzheimer's disease agitation and smoking cessation. It was incorporated in Delaware in January 2012, with offices located at One World Trade Center, New York, New York.

Written from the business description in Axsome Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth

USD 638.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 638.5 · Net income -183.2
250.0M500.0M-150.0M-300.0M
20142017202020232025
Compound annual growth
+133.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -26.1% · Net -28.7%
-100%-200%-300%
201420192025
ROE
FY2025 · ROE -252.1%
-100%-200%-300%
201420192025
Three returns, three denominators.

Each USD of equity lost 252 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -93.9
-100M-200M
201420192025

Total assetsUSD 689.8M
EquityUSD 88.3M
CashUSD 322.9M
Gross debtUSD 187.7M
Net debtUSD -135.2M
Current ratio1.55×

The company holds more cash than debt.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AXSM, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.60.40.30.1◌◌◌◌◌◌◌◌
Operating income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0◌
Income tax $B−0.00.00.00.00.00.00.00.00.00.0◌◌
Net income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $−3.68−5.99−5.27−4.60−3.47−2.77−2.01−1.15−1.27−1.42−1.02−0.66
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−252.1−231.6−159.2−299.0−201.5−70.4−76.1−350.8−151.2−80.0——
Shares out B0.050.050.050.040.040.040.040.030.030.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. 15 checks were skipped: revenue is not tagged before 2022. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image